RU94046321A - Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе - Google Patents

Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе

Info

Publication number
RU94046321A
RU94046321A RU94046321/13A RU94046321A RU94046321A RU 94046321 A RU94046321 A RU 94046321A RU 94046321/13 A RU94046321/13 A RU 94046321/13A RU 94046321 A RU94046321 A RU 94046321A RU 94046321 A RU94046321 A RU 94046321A
Authority
RU
Russia
Prior art keywords
preparing
antibodies
immunization
methods
pharmaceutical composition
Prior art date
Application number
RU94046321/13A
Other languages
English (en)
Other versions
RU2208642C2 (ru
Inventor
Хельмут Экерт
Ch]
Херберт Якше
Эвелин Янзек
At]
Ханс Лейбнер
Дитер Шольц
Original Assignee
Сандоз Лтд. (CH)
Сандоз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210930A external-priority patent/GB9210930D0/en
Priority claimed from GB929210944A external-priority patent/GB9210944D0/en
Priority claimed from GB929210929A external-priority patent/GB9210929D0/en
Application filed by Сандоз Лтд. (CH), Сандоз Лтд. filed Critical Сандоз Лтд. (CH)
Publication of RU94046321A publication Critical patent/RU94046321A/ru
Application granted granted Critical
Publication of RU2208642C2 publication Critical patent/RU2208642C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Моноклональные муриновые антиидиотипические антитела (Ab2), являющиеся "внутренним образом", к моноклональным антителам ВК55-2 (Ab1), способ их получения и применение для профилактической и/или терапевтической иммунизации против ВИЧ-инфекций, против рака эпителиального происхождения и рака мелких клеток легких.

Claims (1)

  1. Моноклональные муриновые антиидиотипические антитела (Ab2), являющиеся "внутренним образом", к моноклональным антителам ВК55-2 (Ab1), способ их получения и применение для профилактической и/или терапевтической иммунизации против ВИЧ-инфекций, против рака эпителиального происхождения и рака мелких клеток легких.
RU94046321/13A 1992-05-22 1993-05-14 МОНОКЛОНАЛЬНОЕ АНТИИДИОТИПИЧЕСКОЕ АНТИТЕЛО Ab2, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЯ ПРОТИВ БОЛЕЗНЕЙ, СОПРОВОЖДАЮЩИХСЯ ЭКСПРЕССИЕЙ Lewis Y6 АНТИГЕНА, И ДЛЯ ОЧИСТКИ ВАРИАНТА BR55-2 АНТИТЕЛА, ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИЙ СОСТАВ RU2208642C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB929210930A GB9210930D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210930.5 1992-05-22
GB929210944A GB9210944D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210929.7 1992-05-22
GB929210929A GB9210929D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210944.6 1992-05-22

Publications (2)

Publication Number Publication Date
RU94046321A true RU94046321A (ru) 1997-01-27
RU2208642C2 RU2208642C2 (ru) 2003-07-20

Family

ID=27266199

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046321/13A RU2208642C2 (ru) 1992-05-22 1993-05-14 МОНОКЛОНАЛЬНОЕ АНТИИДИОТИПИЧЕСКОЕ АНТИТЕЛО Ab2, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЯ ПРОТИВ БОЛЕЗНЕЙ, СОПРОВОЖДАЮЩИХСЯ ЭКСПРЕССИЕЙ Lewis Y6 АНТИГЕНА, И ДЛЯ ОЧИСТКИ ВАРИАНТА BR55-2 АНТИТЕЛА, ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИЙ СОСТАВ

Country Status (20)

Country Link
EP (1) EP0644947B1 (ru)
JP (3) JPH07507207A (ru)
KR (1) KR100279317B1 (ru)
AT (1) ATE179214T1 (ru)
AU (1) AU678160B2 (ru)
CA (1) CA2134751C (ru)
CZ (1) CZ286547B6 (ru)
DE (1) DE69324584T2 (ru)
DK (1) DK0644947T3 (ru)
ES (1) ES2133395T3 (ru)
FI (1) FI111518B (ru)
GR (1) GR3030701T3 (ru)
HU (1) HU219055B (ru)
NO (1) NO316120B1 (ru)
NZ (1) NZ252161A (ru)
PL (1) PL175651B1 (ru)
RU (1) RU2208642C2 (ru)
SG (1) SG50721A1 (ru)
SK (1) SK281086B6 (ru)
WO (1) WO1993024647A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US20080268459A1 (en) * 2003-08-14 2008-10-30 Wyeth Ludwig Institute For Cancer Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
JP5985481B2 (ja) * 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生
RU2735653C2 (ru) * 2016-08-23 2020-11-05 Тран-Сцелл Биологицс Привате Лимитед Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0423198B1 (en) * 1988-07-06 1996-05-08 VERIGEN, INC. (a Corporation of Delaware) Antibodies specific towards hiv 1 gp 48
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.

Also Published As

Publication number Publication date
SK139894A3 (en) 1995-07-11
CA2134751C (en) 2003-12-16
NO316120B1 (no) 2003-12-15
ES2133395T3 (es) 1999-09-16
NZ252161A (en) 1996-10-28
PL175651B1 (pl) 1999-01-29
JPH07507207A (ja) 1995-08-10
AU4068893A (en) 1993-12-30
EP0644947B1 (en) 1999-04-21
FI945485A0 (fi) 1994-11-22
RU2208642C2 (ru) 2003-07-20
CZ286547B6 (cs) 2000-05-17
NO944443L (no) 1995-01-20
JPH11178594A (ja) 1999-07-06
HUT71311A (en) 1995-11-28
EP0644947A1 (en) 1995-03-29
CZ285194A3 (en) 1995-05-17
DK0644947T3 (da) 1999-11-01
DE69324584D1 (de) 1999-05-27
JP2006143738A (ja) 2006-06-08
AU678160B2 (en) 1997-05-22
HU219055B (hu) 2001-02-28
KR950701685A (ko) 1995-04-28
DE69324584T2 (de) 1999-09-23
CA2134751A1 (en) 1993-12-09
FI111518B (fi) 2003-08-15
GR3030701T3 (en) 1999-11-30
ATE179214T1 (de) 1999-05-15
WO1993024647A1 (en) 1993-12-09
SK281086B6 (sk) 2000-11-07
SG50721A1 (en) 2000-11-21
KR100279317B1 (ko) 2001-01-15
NO944443D0 (no) 1994-11-21
FI945485A (fi) 1994-11-22

Similar Documents

Publication Publication Date Title
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
CA2310888A1 (en) Monoclonal human natural antibodies
RU94028282A (ru) Биспецифическое антитело, способ его получения, моноклональные антитела, фармацевтический препарат, фармацевтические наборы, способ удаления опухолевых клеток, применение биспецифического фрагмента антитела
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
SE8700467D0 (sv) Cross-protective human monoclonal antibody compositions
ATE197506T1 (de) Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
RU94046321A (ru) Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе
WO1997025071A3 (en) Immunoconjugate for the treatment of aids
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
ATE218368T1 (de) Medikament welches protein c aktivierendes peptid enthält
CS55990A3 (en) Phenylhydrazones, process of their preparation and cosmetic preparations and pharmaceuticals made therefrom
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
KR890700133A (ko) 인체단일클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료제
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
TW223019B (ru)
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
SU681928A1 (ru) Адъювант

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20060515